An interventional study of Segmental lung recruitment and Conventional lung recruitment in Segmental Lung Atelectasis, sponsored by Clinical Hospital Center Rijeka. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-02.
Sponsored by Clinical Hospital Center Rijeka · Not applicable, Interventional, and Treatment
This study compares two ways of reopening collapsed parts of the lung in patients on a ventilator.
In one group, doctors use a small camera (bronchoscope) to guide air pressure directly to the blocked part of the lung. In the other group, increased air pressure is applied to the whole lung using the ventilator.
Patients are carefully monitored to ensure safety.
This study will compare two lung recruitment strategies in mechanically ventilated patients with segmental atelectasis.
In the experimental group, patients will undergo bronchoscopy-guided targeted segmental recruitment using endobronchial bloker. A flexible bronchoscope will be introduced through the endotracheal tube and advanced under direct visualization to the affected lung segment. The endobronchial blocker will be positioned to temporarily block the segmental bronchus, creating a closed system. Sustained positive pressure of 30 cmH₂O will be applied directly to the atelectatic segment for 30 minutes, while standard ventilator settings will be maintained for the remainder of the lung. Continuous monitoring of oxygen saturation, heart rate, blood pressure, and end-tidal carbon dioxide will be maintained. The maneuver will be immediately discontinued if oxygen saturation decreases by more than 10%, systolic blood pressure decreases by more than 20%, or heart rate changes by more than 20% from baseline values.
In the control group, patients will receive a conventional whole-lung recruitment maneuver. Continuous positive airway pressure (CPAP) of 40 cmH₂O will be applied to the entire respiratory system for 40 seconds using the ventilator. Monitoring and safety criteria will be identical to those used in the experimental group, and the maneuver will be discontinued if predefined thresholds are exceeded.
All patients will receive lung-protective mechanical ventilation according to current guidelines. Tidal volumes will be maintained at 6-8 mL/kg predicted body weight, plateau pressures will be limited to less than 30 cmH₂O, and positive end-expiratory pressure (PEEP) will be adjusted according to FiO₂-PEEP tables. Permissive hypercapnia will be accepted provided arterial pH remains above 7.20.
The primary outcomes will focus on safety and will include the incidence of clinically significant desaturation (oxygen saturation decrease greater than 5% from baseline) and hemodynamic instability (systolic blood pressure decrease greater than 20 mmHg or need for vasopressor dose escalation) during and within 30 minutes after the maneuver.
Secondary outcomes will include changes in respiratory parameters measured at baseline, 24 hours, and 48 hours after the intervention. These parameters will include the PaO₂/FiO₂ ratio, static respiratory system compliance, driving pressure, plateau pressure, and PEEP. Arterial blood gas analysis will be performed at baseline, 1 hour, 24 hours, and 48 hours to assess pH, PaO₂, PaCO₂, bicarbonate, and base excess.
Clinical outcomes will include duration of mechanical ventilation following the maneuver, length of stay in the intensive care unit, duration of ward treatment after ICU discharge, in-hospital mortality, and 28-day all-cause mortality.
All patients will undergo contrast-enhanced chest computed tomography. Lung parenchyma will be segmented using 3D Slicer software to quantify total lung volume and non-ventilated (pathologic) lung regions. The proportion of non-ventilated lung tissue relative to total lung volume will be calculated. A change greater than 15% in the proportion of non-ventilated lung between baseline and follow-up scans will be considered clinically significant.
Venous blood samples will be collected at baseline, 24 hours, and 48 hours. Serum concentrations of interleukin-2 and interleukin-8 will be measured using ELISA assays. Samples will be analyzed in duplicate, and assay variability will be less than 10%.
377 studies on the registry are indexed under Pulmonary Atelectasis; 93 are open to participants now.
This study's planned enrollment of 20 is below the median of 60 across 268 interventional studies indexed under Pulmonary Atelectasis.
Browse Pulmonary Atelectasis studies →Clinical Hospital Center Rijeka is the lead sponsor of 20 studies on the registry; 9 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will undergo bronchoscopy-guided targeted segmental lung recruitment via endobronchial blocker. Flexible bronchoscope will be introduced through the endotracheal tube and advanced under direct visualization to the affected lung segment. The endobronchial blocker will be positioned to temporarily occlude the segmental bronchus, creating a closed system. Sustained positive pressure of 30 cmH₂O will be applied directly to the atelectatic segment for 30 minutes, while standard ventilator settings will be maintained for the remaining lung tissue.
Procedure: Segmental lung recruitment
Patients in the control group will receive standard recruitment maneuvers using continuous positive airway pressure applied for a short, sustained period at a level consistent with conventional clinical practice. This approach will reflect the commonly used recruitment strategy in routine care.
Procedure: Conventional lung recruitment
Patients will undergo bronchoscopy-guided targeted segmental lung recruitment via endobronchial blocker. Flexible bronchoscope will be introduced through the endotracheal tube and advanced under direct visualization to the affected lung segment. The endobronchial blocker will be positioned to temporarily occlude the segmental bronchus, creating a closed system. Sustained positive pressure of 30 cmH₂O will be applied directly to the atelectatic segment for 30 minutes, while standard ventilator settings will be maintained for the remaining lung tissue.
Patients in the control group received standard recruitment maneuvers consisting of continuous positive airway pressure (CPAP) of 40 cmH₂O applied to the entire respiratory system for 40 seconds. This approach represents the conventional recruitment strategy used in clinical practice.
Safety profile
The primary safety outcomes will be the incidence of clinically significant desaturation and hemodynamic instability during and within 30 minutes following the recruitment.
Time frame: From enrollment 72 hours
No study locations are listed for this record.
Plan to share: Undecided
Start is estimated for Feb 2026; primary completion for Mar 2026, 1 month later.
Of 152 non-industry interventional studies with no phase under Pulmonary Atelectasis, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 24. This study's planned 1 month is below that.
Counting every sponsor, half of 154 studies reached it within 12 months; a quarter within 5 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Clinical Hospital Center Rijeka